Clinical Edge Journal Scan

Atopic dermatitis is positively linked with the risk for juvenile idiopathic arthritis


 

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Recommended Reading

AD outcomes improved with lebrikizumab and topical steroids
MDedge Dermatology
Age-related atopic dermatitis phenotypes evaluated in study
MDedge Dermatology
Lebrikizumab+topical corticosteroid shows promise in moderate-to-severe atopic dermatitis
MDedge Dermatology
Abrocitinib rapidly relieves itch in moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib offers a long-term treatment option for moderate-to-severe atopic dermatitis
MDedge Dermatology
Long-term integrated safety of baricitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
Upadacitinib is effective in treating difficult-to-treat moderate-to-severe atopic dermatitis
MDedge Dermatology
Prolonged dupilumab therapy is safe and effective in moderate-to-severe atopic dermatitis
MDedge Dermatology
Childhood atopic dermatitis is associated with increased fatigue
MDedge Dermatology
Atopic dermatitis: No association between dupilumab use and malignancy
MDedge Dermatology